After setbacks, cema-cel might have a path to approval in lymphoma.
ApexOnco Front Page
Recent articles
Optimum-02 virtually replicates phase 1, and a filing will follow.
Arcellx and AstraZeneca take centre stage.
Five years after settling, GSK is again accused of breaching the Jemperli deal.
Meanwhile, Zai Lab faces delays in its pivotal DLL3 trial.
The cash-strapped biotech adds Car-T projects but tries to avoid a lawsuit.
The company adds royalty aggregation to its R&D business.
And AbbVie and Genmab scoop their ASH presentation with new data.
